BlueRiver Acquisition Corp. Shares Halted, News Pending
Save time and jump to the most important pieces.
SC 13G/A - BlueRiver Acquisition Corp. (0001831006) (Subject)
SC 13G/A - BlueRiver Acquisition Corp. (0001831006) (Subject)
SC 13G - BlueRiver Acquisition Corp. (0001831006) (Subject)
425 - BlueRiver Acquisition Corp. (0001831006) (Subject)
8-K - BlueRiver Acquisition Corp. (0001831006) (Filer)
DEF 14A - BlueRiver Acquisition Corp. (0001831006) (Filer)
NYSE American LLC ("NYSE American" or the "Exchange") announced today that the staff of NYSE Regulation has determined to suspend trading in the Class A ordinary shares (NYSE:BLUA) and units (NYSE:BLUA) of BlueRiver Acquisition Corp. (the "Company") from NYSE American. The NYSE American had previously announced on February 2, 2024 an NYSE Regulation determination to delist all of the Company's listed securities, which included Company's Class A ordinary shares, units and redeemable warrants (collectively, "Securities"), and the Company appealed such delisting determination. On July 3, 2024, the NYSE American suspended trading in the Company's redeemable warrants as they were trading at an a
BlueRiver Acquisition Corp. (NYSE:BLUA) (the "Company") announces that, as disclosed in the Company's Current Report on Form 8-K filed on February 7, 2024 with the United States Securities and Exchange Commission, the Company received a letter from the NYSE American LLC ("NYSE American" or the "Exchange") on February 2, 2024, stating that the staff of NYSE Regulation has determined to commence proceedings to delist the Company's Common Stock, Units and Rights (collectively, the "Securities") pursuant to Sections 119(b) and 119(f) of the NYSE American Company Guide because the Company failed to consummate a business combination within 36 months of the effectiveness of its initial public offe
Spinal Stabilization Technologies is a pioneer in developing minimally invasive surgical treatments for specific types of lower back pain. It is targeting a promising market opportunity within the areas of Augmented Discectomy and Degenerative Disc Disease. In March 2021, the FDA granted the PerQdisc Nucleus Replacement System, the Company's leading product candidate, designation as a Breakthrough Device, potentially allowing for a more streamlined FDA review process and reduced regulatory costs. Proposed transaction represents a pre-money equity value of $240 million for Spinal Stabilization Technologies. Existing Spinal Stabilization Technologies shareholders will roll 100% o
NYSE American LLC ("NYSE American" or the "Exchange") announced today that the staff of NYSE Regulation has determined to suspend trading in the Class A ordinary shares (NYSE:BLUA) and units (NYSE:BLUA) of BlueRiver Acquisition Corp. (the "Company") from NYSE American. The NYSE American had previously announced on February 2, 2024 an NYSE Regulation determination to delist all of the Company's listed securities, which included Company's Class A ordinary shares, units and redeemable warrants (collectively, "Securities"), and the Company appealed such delisting determination. On July 3, 2024, the NYSE American suspended trading in the Company's redeemable warrants as they were trading at an ab
Spinal Stabilization Technologies ("SST" or the "Company"), a medical device company, and BlueRiver Acquisition Corp. ("BlueRiver") (NYSE AM: BLUA), a publicly traded special purpose acquisition company, have entered into a definitive business combination agreement. Upon the closing of the proposed transaction between SST and BlueRiver, the combined company will operate as Spinal Stabilization Technologies and be listed on an approved stock exchange.